Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Flagrante Delictu who wrote (21369)	5/25/1998 2:21:00 AM
From: Peter Singleton	Read Replies (1) \| Respond to of 32384

fyi ... biz.yahoo.com Monday May 25, 1:54 am Eastern Time Takeda Chem, Eli Lilly to promote diabetes drug TOKYO, May 25 (Reuters) - Takeda Chemical Industries Ltd (4502.T) said on Monday that it and Eli Lilly and Co had agreed to jointly promote Takeda's new diabetes drug Actos in the United States. Takeda aims to start selling the drug by the beginning of the next century, the company said in a statement. Takeda also said it would set up a new company and make it a wholly owned subsidiary of Takeda America Holdings Inc. The new firm, Takeda Pharmaceuticals America Inc, will market Actos once it gets U.S. approval. Promoting the drug includes collecting clinical data on the drug, which must be done before its launch.